Kannalife Secures Funding of $1.49 Million from The Michael J. Fox Foundation for Parkinson’s Research
June 25, 2024 08:30 ET
|
Kannalife Sciences, Inc.
Funding of $1.49 million USD to support the development of KLS-13019 targeting neuroinflammation and mitochondrial dysfunction Kannalife has developed a new class of orally bioavailable...
Kannalife Sciences Discusses Orphan Drug Opportunity for KLS-13019
August 11, 2015 13:50 ET
|
KannaLife Sciences, Inc.
NEW YORK, Aug. 11, 2015 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc., a Phyto-Medical Company, describes orphan drug opportunity for KLS-13019, a Novel Functionalized 1,3-Benzene Diol for the...
KannaLife Sciences Announces Publication of Its Global PCT Patent Covering Cannabidiol-like Neuroprotective Agents
August 06, 2015 13:54 ET
|
KannaLife Sciences, Inc.
NEW YORK, Aug. 6, 2015 (GLOBE NEWSWIRE) -- KannaLife Sciences, Inc., a Phyto-Medical Company, announced the publication of its global WIPO/PCT Patent WO2015/106108A2 – 'Novel Functionalized...